雙眼他莫昔芬視網膜病變多模式影像檢查一例_Chinese Journal of Ocular Fundus Diseases

Authors：

孫功鵬 , 易佐慧子 , 鄭紅梅 ,  陳長征

武漢大學人民醫院眼科中心 430060;

Corresponding?author：

陳長征, Email: whuchenchzh@163.com

Keywords：

他莫昔芬; 視網膜疾病; 病例報告

DOI：

10.3760/cma.j.cn511434-20190916-00290

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 孫功鵬, 易佐慧子, 鄭紅梅, 陳長征. 雙眼他莫昔芬視網膜病變多模式影像檢查一例. Chinese Journal of Ocular Fundus Diseases, 2021, 37(1): 61-63. doi: 10.3760/cma.j.cn511434-20190916-00290 Copy

1.	Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy[J]. Cancer Treat Rep, 1978, 62(3): 315-320.
2.	Bommireddy T, Carrim ZI. To stop or not? Tamoxifen therapy for secondary prevention of breast cancer in a patient with ocular toxicity[J/OL]. BMJ Case Rep, 2016, 2016:bcr2015213431[2016-01-11]. http://europepmc.org/article/MED/26759403. DOI: 10.1136/bcr-2015-213431 .
3.	Nayfield SG, Gorin MB. Tamoxifen-associated eye disease: a review[J]. J Clin Oncol, 1996, 14(3): 1018-1026. DOI: 10.1200/JCO.1996.14.3.1018.
4.	Doshi RR, Fortun JA, Kim BT, et al. Pseudocystic foveal cavitation in tamoxifen retinopathy[J]. Am J Ophthalmol, 2014, 157(6): 1291-1298. DOI: 10.1016/j.ajo.2014.02.046.
5.	Cho KS, Yoon YH, Choi JA, et al. Induction of autophagy and cell death by tamoxifen in cultured retinal pigment epithelial and photoreceptor cells[J]. Invest Ophthalmol Vis Sci, 2012, 53(9): 5344-5353. DOI: 10.1167/iovs.12-9827.
6.	Kim LA, Amarnani D, Gnanaguru G, et al. Tamoxifen toxicity in cultured retinal pigment epithelial cells is mediated by concurrent regulated cell death mechanisms[J]. Invest Ophthalmol Vis Sci, 2014, 55(8): 4747-4758. DOI: 10.1167/iovs.13-13662.
7.	Gualino V, Cohen SY, Delyfer MN, et al. Optical coherence tomography findings in tamoxifen retinopathy[J]. Am J Ophthalmol, 2005, 140(4): 757-758. DOI: 10.1016/j.ajo.2005.04.042.
8.	Dyer MA, Cepko CL. Control of Müller glial cell proliferation and activation following retinal injury[J]. Nat Neurosci, 2000, 3(9): 873-880. DOI: 10.1038/78774.
9.	Lee S, Kim HA, Yoon YH. OCT angiography findings of tamoxifen retinopathy: similarity with macular telangiectasia type 2[J]. Ophthalmol Retina, 2019, 3(8): 681-689. DOI: 10.1016/j.oret.2019.03.014.
10.	Kovach JL, Isildak H, Sarraf D, et al. Crystalline retinopathy: unifying pathogenic pathways of disease[J]. Surv Ophthalmol, 2019, 64(1): 1-29. DOI: 10.1016/j.survophthal.2018.08.001.
11.	Jack LS, Benson C, Sadiq MA, et al. Segmentation of retinal layers in sj?gren-larsson syndrome[J]. Ophthalmology, 2015, 122(8): 1730-1732. DOI: 10.1016/j.ophtha.2015.02.003.
12.	吉宇瑩, 張雄澤, 李妙玲, 等. 2型黃斑毛細血管擴張癥眼底及影像特征觀察[J]. 中華眼底病雜志, 2016, 32(4): 382-386. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.009.Ji YY, Zhang XZ, Li ML, et al. Characteristics of fundus image in macular telangiectasia type 2[J]. Chin J Ocul Fundus Dis, 2016, 32(4): 382-386. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.009.
13.	Kim HA, Lee S, Eah KS, et al. Prevalence and risk factors of tamoxifen retinopathy[J]. Ophthalmology, 2020, 127(4): 555-557. DOI: 10.1016/j.ophtha.2019.10.038.
14.	Davies C, Pan H, Godwin J, et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-816. DOI: 10.1016/S0140-6736(12)61963-1.
15.	周慧穎, 葉俊杰, 陳有信. 雙眼他莫昔芬視網膜病變一例[J]. 中華眼科雜志, 2017, 53(7): 548-550. DOI: 10.3760/cma.j.issn.0412-4081.2017.07.014.Zhou HY, Ye JJ, Chen YX. A case of bilateral tamoxifen retinopathy[J]. Chin J Ophlthalmol, 2017, 53(7): 548-550. DOI: 10.3760/cma.j.issn.0412-4081.2017.07.014.

1. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy[J]. Cancer Treat Rep, 1978, 62(3): 315-320.
2. Bommireddy T, Carrim ZI. To stop or not? Tamoxifen therapy for secondary prevention of breast cancer in a patient with ocular toxicity[J/OL]. BMJ Case Rep, 2016, 2016:bcr2015213431[2016-01-11]. http://europepmc.org/article/MED/26759403. DOI: 10.1136/bcr-2015-213431 .
3. Nayfield SG, Gorin MB. Tamoxifen-associated eye disease: a review[J]. J Clin Oncol, 1996, 14(3): 1018-1026. DOI: 10.1200/JCO.1996.14.3.1018.
4. Doshi RR, Fortun JA, Kim BT, et al. Pseudocystic foveal cavitation in tamoxifen retinopathy[J]. Am J Ophthalmol, 2014, 157(6): 1291-1298. DOI: 10.1016/j.ajo.2014.02.046.
5. Cho KS, Yoon YH, Choi JA, et al. Induction of autophagy and cell death by tamoxifen in cultured retinal pigment epithelial and photoreceptor cells[J]. Invest Ophthalmol Vis Sci, 2012, 53(9): 5344-5353. DOI: 10.1167/iovs.12-9827.
6. Kim LA, Amarnani D, Gnanaguru G, et al. Tamoxifen toxicity in cultured retinal pigment epithelial cells is mediated by concurrent regulated cell death mechanisms[J]. Invest Ophthalmol Vis Sci, 2014, 55(8): 4747-4758. DOI: 10.1167/iovs.13-13662.
7. Gualino V, Cohen SY, Delyfer MN, et al. Optical coherence tomography findings in tamoxifen retinopathy[J]. Am J Ophthalmol, 2005, 140(4): 757-758. DOI: 10.1016/j.ajo.2005.04.042.
8. Dyer MA, Cepko CL. Control of Müller glial cell proliferation and activation following retinal injury[J]. Nat Neurosci, 2000, 3(9): 873-880. DOI: 10.1038/78774.
9. Lee S, Kim HA, Yoon YH. OCT angiography findings of tamoxifen retinopathy: similarity with macular telangiectasia type 2[J]. Ophthalmol Retina, 2019, 3(8): 681-689. DOI: 10.1016/j.oret.2019.03.014.
10. Kovach JL, Isildak H, Sarraf D, et al. Crystalline retinopathy: unifying pathogenic pathways of disease[J]. Surv Ophthalmol, 2019, 64(1): 1-29. DOI: 10.1016/j.survophthal.2018.08.001.
11. Jack LS, Benson C, Sadiq MA, et al. Segmentation of retinal layers in sj?gren-larsson syndrome[J]. Ophthalmology, 2015, 122(8): 1730-1732. DOI: 10.1016/j.ophtha.2015.02.003.
12. 吉宇瑩, 張雄澤, 李妙玲, 等. 2型黃斑毛細血管擴張癥眼底及影像特征觀察[J]. 中華眼底病雜志, 2016, 32(4): 382-386. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.009.Ji YY, Zhang XZ, Li ML, et al. Characteristics of fundus image in macular telangiectasia type 2[J]. Chin J Ocul Fundus Dis, 2016, 32(4): 382-386. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.009.
13. Kim HA, Lee S, Eah KS, et al. Prevalence and risk factors of tamoxifen retinopathy[J]. Ophthalmology, 2020, 127(4): 555-557. DOI: 10.1016/j.ophtha.2019.10.038.
14. Davies C, Pan H, Godwin J, et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-816. DOI: 10.1016/S0140-6736(12)61963-1.
15. 周慧穎, 葉俊杰, 陳有信. 雙眼他莫昔芬視網膜病變一例[J]. 中華眼科雜志, 2017, 53(7): 548-550. DOI: 10.3760/cma.j.issn.0412-4081.2017.07.014.Zhou HY, Ye JJ, Chen YX. A case of bilateral tamoxifen retinopathy[J]. Chin J Ophlthalmol, 2017, 53(7): 548-550. DOI: 10.3760/cma.j.issn.0412-4081.2017.07.014.

Previous Article
“網球拍”式硅油攔截縫線手術治療外傷性晶狀體虹膜隔缺如二例
Next Article
Progress in diagnosis and treatment of diabetic retinopathy with leukemia

Chinese Journal of Ocular Fundus Diseases

雙眼他莫昔芬視網膜病變多模式影像檢查一例

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content